This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Proton pump inhibitors in gastro-oesophageal reflux disease

Authoring team

  • acid suppression is the basis of treatment for GORD, and can be achieved effectively with proton pump inhibitors (PPIs) (1)
  • some of the PPIs available include-omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole (1)
  • they should be taken before meals
    • generally before breakfast if taken once daily (1)
  • a healing dose of a proton pump inhibitor (PPI) should be prescribed in patients with severe symptoms of gastro-oesophageal reflux disorder (GORD) or who have proven pathology (2) (oesophageal ulceration or Barrett's oesophagus)
  • after symptomatic control has been achieved then the dose should be reduced to the lowest dose that allows symptomatic control
  • the higher healing dose should be recommenced if there is a recurrence of GORD symptoms
  • in cases of complicated oesophagitis (e.g. haemorrhage, stricture) the the higher healing dose should be maintained
  • in patients who do not have proven pathology/mild symptoms of GORD then often alternative therapies to PPIs can be used in management e.g. alginates, antacids, H2 receptor antagonists
  • in severe cases a H2-antagonist may be used in addition
  • in some patients, gastric motility stimulants may be effective, by increasing the rate of gastric emptying and hence, reducing the opportunity for reflux. Metoclopramide and domperidone, may be of use in stimulation of gastric emptying, particularly in patients with systemic sclerosis, diabetes mellitus, and autonomic neuropathy. Cisapride has been withdrawn from marketing in the UK (3)
  • since GORD is a chronic condition, continuous, even lifelong, therapy may be necessary (1)
    • on-demand versus continuous maintenance therapy with a PPI:
      • there is evidence from a systematic review that on-demand maintenance therapy with a PPI is more effective than placbo for controlling symptoms. Also on-demand PPI therapy is as effective as continuous PPI therapy in patients with non-erosive GORD but not those with more severe disease (4)

Note:

  • treatment of reflux oesophagitis with omeprazole in patients who are H. pylori positive increases the risk of atrophic gastritis (5)

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.